Skip to main content

Patients Discovering Breast CancerTrials.org

Web Exclusives - Breast Cancer

SAN ANTONIO—A rapidly growing, nationwide clinical trial matching service that is user-friendly for patients is enabling more patients to learn about and enroll in clinical trials, said Ellie Cohen, PhD, the program's director. Cohen described the success of her program at the 33rd annual San Antonio Breast Cancer Symposium.

BreastCancerTrials.org is a web-based clinical trials matching service designed to empower patients and increase trial participation. Patients find trials looking for participants with their medical situation and connect with research sites. The site was launched in 2008 by the Carol Franc Buck Breast Care Center at the University of California San Francisco National Center of Excellence in Women's Health in collaboration with Quantum Leap Healthcare Collaborative.

"Thousands of patients have adopted BreastCancerTrials.org and they use it to monitor trial opportunities. Our portfolio of breast cancer trials is diverse and growing," Cohen said. "The purpose is to help patients who might not hear about trials from their doctors."

The total number of visitors to date is more than 35,000. Of patients who start a health history, 61% complete it and are matched to trials and, of this group, 41% find at least one trial interesting enough to view the site contact information. Cohen does not have information as to how many patients actually enroll, and the numbers reflect only users who complete the application in one visit.

What The Site Offers

The online forms are customized depending on whether the user is recently diagnosed, managing metastatic disease, or has completed treatment. Women can choose whether to use the service anonymously or to save their health history by providing an e-mail address. They are matched with trials appropriate for their disease and can view research site information, including the closest research site and distance from the patient's home.

The trial portfolio includes 450 trials, including 275 treatment trials, 84 psychosocial/supportive trials, 32 evaluating diagnosis/screening, 22 assessing preventive approaches, and 37 in other categories.

"Trials are for all patients," Cohen stressed. "There is a big myth that they are only for patients who run out of options, but 40% of our trials are in the neoadjuvant and adjuvant setting. Wherever you are on the cancer journey, there is an opportunity to participate in a clinical trial. We want patients to consider trials as a routine option for their breast cancer care."

Users can share their BreastCancerTrials.org history with participating research sites through the SecureConnnect message service. This enables the first screening interview to be simplified as well as efficient, and the user can leave a personal message for the research site, such as, "I don't have health insurance. Can I still enroll?"

The website now also has a weekly trial alert service that informs users when newly listed trials match their health history. The service has more than 1600 subscribers, and 85% of users who save a BreastCancerTrials.org history sign up for these alerts, she said.

"The trial alert service has been responsible for a 68% increase in users," according to Cohen. "It's prompting users to log in and view newly posted trials."

During the first year, there were 4587 returning users and this increased to 7736 in year 2 after the trial alert service was launched.

Who is Using BreastCancerTrials.org?

By disease stage, 440 of 1814 users (who saved their history) were stage 0 to III and recently diagnosed; 746 had completed treatment for stage 0 to III disease; and 628 were living with metastatic disease.

Most current users are 50 to 69 years old, with women aged 40 to 49 a close second. Most users have been white (non-Hispanic) women with some college education. Fewer than 10% have no more than a high school degree. "Our early adopters are educated and white, but we hope to change this through outreach to underserved populations," Cohen said.

Related Items
HER2 Heartbreak? Understanding the Management of Cardiotoxicity From Trastuzumab in HER2-Positive Breast Cancer
JHOP - June 2026 Vol 16, No 3 published on January 21, 2026 in Symptom Management Overview, Breast Cancer, Targeted Therapies
Response to Alectinib in Refractory Breast Cancer With an EML4-ALK Rearrangement
JHOP - December 2025 Vol 15, No 6 published on September 29, 2025 in Case Reports, Breast Cancer, Tyrosine Kinase Inhibitor, Targeted Therapies
Simvastatin-Induced Rhabdomyolysis Potentially Triggered by Palbociclib Inhibition of CYP3A4: A Case Report
JHOP - February 2026 Vol 16, No 1 published on September 19, 2025 in Case Reports, Adverse Events, Drug–Drug Interaction, Breast Cancer
Highly Effective Treatment for Bone-Only Signet Ring Cell Breast Cancer With Ribociclib, Fulvestrant, and Denosumab: A Case Study
JHOP - October 2025 Vol 15, No 5 published on July 17, 2025 in Case Reports, Breast Cancer, Chemotherapy
Incidence of Febrile Neutropenia in Patients With Grade 3 or 4 Neutropenia Who Are Receiving Palbociclib
JHOP - October 2024 Vol 14, No 5 published on October 11, 2024 in Original Research, Adverse Events, Breast Cancer, CDK4/6 Inhibitors, Oncology Pharmacy Programs/Protocols
Exemestane Treatment in a Male Patient With Concurrent Breast and Prostate Cancers: A Case Report
JHOP - August 2024 Vol 14, No 4 published on August 2, 2024 in Case Reports, Breast Cancer, Prostate Cancer
Evaluation of Pharmacist-Driven Approach to Monitoring for Neutropenia Related to CDK4/6 Inhibitors in Women With Advanced Breast Cancer
JHOP - June 2024 Vol 14, No 3 published on May 23, 2024 in Practical Issues in Pharmacy Management, Oncology Pharmacy Programs/Protocols, Breast Cancer, CDK4/6 Inhibitors, Adverse Events
Real-world Outcomes Following Initiation of Abemaciclib in Patients With Brain Metastases Secondary to HR+/HER2- Metastatic Breast Cancer
Hope S. Rugo, MD
Videos published on February 9, 2024 in Rapid Reactions, Breast Cancer
Primary Analysis of HER2CLIMB-02: Addition of Tucatinib to Trastuzumab Emtansine in Previously Treated Patients with HER2-Positive Metastatic Breast Cancer
Sara M. Tolaney, MD, MPH
Videos published on February 8, 2024 in Rapid Reactions, Breast Cancer
INAVO120 Phase III Study: Treatment of Patients With PIK3CA-mutant, HR+/HER2- Locally Advanced or Metastatic Breast Cancer With Invavolisib in Combination With Palbociclib and Fulvestrant
Hope S. Rugo, MD
Videos published on February 7, 2024 in Rapid Reactions, Breast Cancer